摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-4-iodo-6-methoxy-5-(methoxymethyl)pyridine | 144290-14-2

中文名称
——
中文别名
——
英文名称
2-chloro-4-iodo-6-methoxy-5-(methoxymethyl)pyridine
英文别名
6-chloro-4-iodo-2-methoxy-3-(methoxymethyl)pyridine
2-chloro-4-iodo-6-methoxy-5-(methoxymethyl)pyridine化学式
CAS
144290-14-2
化学式
C8H9ClINO2
mdl
——
分子量
313.522
InChiKey
QPAGFOXOFQGBMW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    318.4±37.0 °C(Predicted)
  • 密度:
    1.743±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of pyridylglyoxylic acid derivatives via a palladium-catalysed double carbonylation of iodopyridines
    作者:Samuel Couve-Bonnaire、Jean-François Carpentier、Yves Castanet、André Mortreux
    DOI:10.1016/s0040-4039(99)00596-1
    日期:1999.5
    4-Iodopyridiens react with CO and HNEt2 or in the presence of a catalytic amount of PdCl2(PPh3)2 to give the corresponding α-keto amides and esters in fair to high yields.
    4-碘吡啶鎓与CO和HNEt 2或在催化量的PdCl 2(PPh 3)2存在下反应,以相当高的收率得到相应的α-酮酰胺和酯。
  • Intermediates and method of making camptothecin and camptothecin analogs
    申请人:North Carolina State University
    公开号:US05162532A1
    公开(公告)日:1992-11-10
    Compounds of Formula I ##STR1## are made in accordance with the following scheme: ##STR2## wherein R may be loweralkyl; R.sub.1 may be H, loweralkyl, loweralkoxy, or halo; R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may each independently be H, amino, hydroxy, loweralkyl, loweralkoxy, loweralkylthio, di(loweralkyl)amino, cyano, methylenedioxy, formyl, nitro, halo, trifluoromethyl, aminomethyl, azido, amido, hydrazino, or any of the twenty standard amino acids bonded to the A ring via the amino-nitrogen atom; Y is H and W and X are halogen. Also disclosed are novel processes for making starting materials for the scheme given above, and novel intermediates employed in these processes.
    根据以下方案制备Formula I的化合物##STR1##:##STR2##其中R可以是较低的烷基;R.sub.1可以是H、较低的烷基、较低的烷氧基或卤素;R.sub.2、R.sub.3、R.sub.4和R.sub.5可以分别是H、氨基、羟基、较低的烷基、较低的烷氧基、较低的烷硫基、二(较低的烷基)氨基、氰基、亚甲二氧基、甲酰基、硝基、卤素、三氟甲基、氨甲基、叠氮基、酰胺基、叠氮基或通过氨基氮原子与A环键合的二十种标准氨基酸中的任何一种;Y为H,W和X为卤素。还公开了用于制备上述方案的起始材料的新工艺,以及在这些工艺中使用的新中间体。
  • Methods and intermediates for the assymmetric synthesis of camptothecin
    申请人:North Carolina State University
    公开号:US05212317A1
    公开(公告)日:1993-05-18
    Processes for making compounds of Formulae XIV, XV, and XVII ##STR1## wherein R.sub.6 is lower alkyl, R.sub.7 is lower alkyl, R is lower alkyl, Y is H, F or Cl, R.sub.8 is a moiety of Formula XVIII ##STR2## wherein n is 1, 2, or 3, R.sub.11 is C.sub.1 -C.sub.4 alkyl and R.sub.12 is the same as R.sub.11, or R.sub.11 and R.sub.12 together form cyclopentane or cyclohexane, and R.sub.13 is: (a) phenyl substituted 1 to 5 times with C.sub.3 -C.sub.7 secondary alkyl or C.sub.4 -C.sub.7 tertiary alkyl, or (b) selected from the group consisting of naphthyl, anthryl, and phenanthryl optionally substituted 1 to 5 times with C.sub.3 -C.sub.7 secondary alkyl or C.sub.4 -C.sub.7 tertiary alkyl groups, R.sub.10 is C.sub.6 -C.sub.10 alkyl, aryl or alkyl aryl, and Y is H, F or Cl, are disclosed. These processes can be used to make optically enhanced and optically pure forms of the compounds, which are useful in the making of camptothecin and analogs thereof.
    制备式XIV、XV和XVII的化合物的过程,其中R.sub.6是较低的烷基,R.sub.7是较低的烷基,R是较低的烷基,Y是H、F或Cl,R.sub.8是式XVIII的基团,其中n为1、2或3,R.sub.11是C.sub.1-C.sub.4烷基,R.sub.12与R.sub.11相同,或者R.sub.11和R.sub.12共同形成环戊烷或环己烷,R.sub.13为:(a)苯基,用C.sub.3-C.sub.7次生烷基或C.sub.4-C.sub.7三级烷基取代1至5次,或者(b)选自萘基、蒽基和菲基,可选择地用C.sub.3-C.sub.7次生烷基或C.sub.4-C.sub.7三级烷基基团取代1至5次,R.sub.10为C.sub.6-C.sub.10烷基、芳基或烷基芳基,Y为H、F或Cl。这些过程可用于制备这些化合物的光学增强和光学纯形式,这些化合物在紫杉醇及其类似物的制备中很有用。
  • Camptothecin intermediate and method of making camptothecin intermediates
    申请人:North Carolina State University
    公开号:US05191082A1
    公开(公告)日:1993-03-02
    Compounds of Formula I ##STR1## are made in accordance with the following scheme: ##STR2## wherein R may be loweralkyl; R.sub.1 may be H, loweralkyl, loweralkoxy, or halo; R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may each independently be H, amino, hydroxy, loweralkyl, loweralkoxy, loweralkylthio, di(loweralkyl)amino, cyano, methylenedioxy, formyl, nitro, halo, trifluoromethyl, aminomethyl, azido, amido, hydrazino, or any of the twenty standard amino acids bonded to the A ring via the amino-nitrogen atom; Y is H and W and X are halogen. Also disclosed are novel processes for making starting materials for the scheme given above, and novel intermediates employed in these processes.
    化合物I的配方如下:##STR1##是根据以下方案制备的:##STR2##其中R可以是低碳基;R.sub.1可以是H,低碳基,低碳氧基,或卤素;R.sub.2,R.sub.3,R.sub.4和R.sub.5可以各自独立地为H,氨基,羟基,低碳基,低碳氧基,低碳硫基,二(低碳基)氨基,氰基,亚甲二氧基,甲酰基,硝基,卤素,三氟甲基,氨甲基,叠氮基,酰胺基,肼基,或通过氨基氮原子与A环结合的20种标准氨基酸之一;Y是H,W和X是卤素。还披露了制备上述方案的起始材料的新方法,以及在这些过程中使用的新中间体。
  • Camptothecin intermediates and method of making same
    申请人:North Carolina State University
    公开号:US05200524A1
    公开(公告)日:1993-04-06
    Compounds of Formula I ##STR1## are made in accordance with the following scheme: ##STR2## wherein R may be loweralkyl; R.sub.1 may be H, loweralkyl, loweralkoxy, or halo; R.sub.2, R.sub.3, R.sub.4, and R.sub.5 may each independently be H, amino, hydroxy, loweralkyl, loweralkoxy, loweralkylthio, di(loweralkyl)amino, cyano, methylenedioxy, formyl, nitro, halo, trifluormethyl, aminomethyl, azido, amido, hydrazino, or any of the twenty standard amino acids bonded to the A ring via the amino-nitrogen atom; Y is H and W and X are halogen. Also disclosed are novel processes for making starting materials for the scheme given above, and novel intermediate employed in these processes.
    化学式为I的化合物按照以下方案制备:其中R可以是低碳基;R1可以是氢、低碳基、低碳氧基或卤素;R2、R3、R4和R5可以各自独立地是氢、氨基、羟基、低碳基、低碳氧基、低碳硫基、二(低碳基)氨基、氰基、亚甲二氧基、甲酰基、硝基、卤素、三氟甲基、氨甲基、叠氮基、酰胺基、肼基或通过氨基-氮原子与A环结合的二十种标准氨基酸之一;Y为氢,W和X为卤素。此外,还披露了用于上述方案的起始材料的新工艺以及在这些工艺中使用的新中间体。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-